Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Gynecol Endocrinol ; 32(3): 171-6, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26492849

RESUMO

Significant improvements in therapy and life expectancy of ß-thalassemia patients in last decades result in the need of commitment for gynecologists and obstetricians as the complexity of organ impairment needs a specific multidisciplinary approach. After a review of clinical manifestations of ß-thalassemia from a gynecologic point of view, we present the experience of a gynecologic center in treating ß-thalassemia patients from more than 20 years.


Assuntos
Talassemia beta/fisiopatologia , Adolescente , Adulto , Feminino , Ferritinas/sangue , Fertilidade , Ginecologia , Terapia de Reposição Hormonal , Hormônios/sangue , Humanos , Ciclo Menstrual , Estudos Retrospectivos , Adulto Jovem , Talassemia beta/sangue , Talassemia beta/tratamento farmacológico
2.
Gynecol Endocrinol ; 29(2): 119-24, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22946682

RESUMO

In western women, the endometrium is frequently exposed, even after menopause, to the endogenous hormonal stimulation. Such a stimulation increases the risk of pathologic conditions such as endometrial hyperplasia and type I (endometrioid) endometrial adenocarcinoma. Metabolic syndrome, obesity, insulin resistance and type II diabetes promote the endometrial stimulation, and are recognized risk factors for endometrial cancer. Furthermore, chronic hyperinsulinemia linked both to obesity and metabolic syndrome influences endometrial proliferation through direct and indirect actions. Intentional weight loss, calorie restriction and physical activity are associated with a reduced risk of the endometrial pathology. Biological mechanisms include reduction in insulin and sex steroid hormone levels. In addition to life-style modifications, the antidiabetic metformin may be proposed as preventive agent. Metformin reduces the metabolic syndrome, lowers insulin and testosterone levels in postmenopausal women, and it is a potent inhibitor of endometrial cancer cell proliferation.


Assuntos
Endométrio/efeitos dos fármacos , Estilo de Vida , Metformina/uso terapêutico , Pós-Menopausa , Substâncias Protetoras/uso terapêutico , Doenças Uterinas/prevenção & controle , Anticarcinógenos/uso terapêutico , Carcinoma Endometrioide/epidemiologia , Carcinoma Endometrioide/patologia , Carcinoma Endometrioide/prevenção & controle , Neoplasias do Endométrio/epidemiologia , Neoplasias do Endométrio/patologia , Neoplasias do Endométrio/prevenção & controle , Endométrio/patologia , Medicina Baseada em Evidências , Feminino , Humanos , Hiperplasia , Fatores de Risco , Doenças Uterinas/epidemiologia , Doenças Uterinas/patologia
3.
Gynecol Endocrinol ; 23 Suppl 1: 22-31, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17943536

RESUMO

Biological and epidemiological findings suggest that metabolic factors - insulin, insulin-like growth factor-I (IGF-I) and sex hormone-binding globulin (SHBG) - are involved in the development and promotion of breast cancer. Estrogens, particularly if administered orally, counteract metabolic factors that increase breast cancer risk, i.e. they reduce insulin and IGF-I and increase SHBG. This could contribute toward explaining epidemiological data showing that unopposed oral estrogens do not increase breast cancer risk, or do so only modestly. In contrast to natural progesterone and progesterone-derived progestins, progestins endowed with androgenic (or glucocorticoid) activity negatively influence these metabolic factors, counteracting the favorable effects of estrogens. While most biological and epidemiological findings suggest that natural progesterone does not augment breast cancer risk, available data show an increased risk with synthetic progestins - with the possible exception of progesterone-derived dydrogesterone. Different mechanisms for different progestins could possibly be involved. Differences from progesterone with regard to pharmacokinetics and pharmacodynamics, potency, interaction with the two isoforms of the progesterone receptor, and binding to other steroid receptors could all be relevant. These remain theoretical speculations for the time being, but the possibility that some progestins increase breast cancer risk through their negative influence on metabolic factors cannot be rejected.


Assuntos
Neoplasias da Mama/metabolismo , Fator de Crescimento Insulin-Like I/metabolismo , Insulina/metabolismo , Progestinas/farmacologia , Globulina de Ligação a Hormônio Sexual/metabolismo , Neoplasias da Mama/induzido quimicamente , Neoplasias da Mama/prevenção & controle , Interações Medicamentosas , Estrogênios/farmacologia , Feminino , Humanos , Fatores de Risco
4.
J Steroid Biochem Mol Biol ; 97(5): 441-50, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16249080

RESUMO

In the last two decades the prevailing opinion, supported by the "estrogen augmented by progesterone" hypothesis, has been that progesterone contributes to the development of breast cancer (BC). Support for this opinion was provided by the finding that some synthetic progestins, when added to estrogen in hormone replacement therapy (HRT) for menopausal complaints, increase the BC risk more than estrogen alone. However, recent findings suggest that both the production of progesterone during pregnancy and the progesterone endogenously produced or exogenously administered outside pregnancy, does not increase BC risk, and could even be protective. The increased BC risk found with the addition of synthetic progestins to estrogen in HRT seems in all likelihood due to the fact that these progestins (medroxyprogesterone acetate and 19-nortestosterone-derivatives) are endowed with some non-progesterone-like effects which can potentiate the proliferative action of estrogens. The use of progestational agents in pregnancy, for example to prevent preterm birth, does not cause concern in relation to BC risk.


Assuntos
Neoplasias da Mama/induzido quimicamente , Progesterona/efeitos adversos , Progestinas/uso terapêutico , Terapia de Reposição de Estrogênios/efeitos adversos , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Gravidez , Progesterona/uso terapêutico , Progestinas/efeitos adversos , Fatores de Risco
5.
Maturitas ; 51(2): 127-34, 2005 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-15917152

RESUMO

OBJECTIVES: To investigate the effect on hot flushes of a soy isoflavone extract alone (Study A) and with the addition of a supplement of polyunsaturated fatty acids, PUFAs (Study B). METHODS: Subjects were postmenopausal women (29 in Study A, 28 in Study B) with more than five troublesome hot flushes per day. Both studies were double-blind randomized placebo-controlled trials with cross-over design, of 24-week duration. After a 2-week observation period, they were randomized to receive two capsules per day providing 60mg of isoflavones or placebo for 12 weeks; thereafter, women who had taken isoflavones were given placebo for a second 12-week period, and vice-versa. Women in the Study B were given also two capsules per day containing a PUFA supplement for the entire 24-week test period. RESULTS: Both studies showed the isoflavone extract to have no greater efficacy on hot flushes than the placebo. During the 24 weeks of the Study B there was a progressive and highly significant reduction in the number of hot flushes, independent of whether the women had begun with isoflavones or with placebo. CONCLUSION: In these two trials the isoflavone extract did not show greater efficacy on the hot flushes than the placebo. The reduction of hot flushes observed in the Study B might be due to the PUFA supplement. PUFAs, particularly Omega (Omega) 3-fatty acids, could reduce hot flushes through their influence on neuronal membranes and/or the modulation of the neurotransmitter function and the serotoninergic system. Studies specifically designed to document the action of PUFAs on hot flushes would be welcome.


Assuntos
Suplementos Nutricionais , Ácidos Graxos Insaturados/uso terapêutico , Glycine max , Fogachos/terapia , Isoflavonas/uso terapêutico , Índice de Massa Corporal , Estudos Cross-Over , Método Duplo-Cego , Ácidos Graxos Insaturados/administração & dosagem , Feminino , Fogachos/prevenção & controle , Humanos , Pessoa de Meia-Idade , Extratos Vegetais/administração & dosagem , Extratos Vegetais/uso terapêutico , Pós-Menopausa , Resultado do Tratamento
6.
Maturitas ; 46 Suppl 1: S39-44, 2003 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-14670644

RESUMO

OBJECTIVE: Circulating insulin-like growth factor-I (IGF-I) is mainly produced by the liver under GH stimulation and is influenced by nutrition and insulin. IGF-I bioavailability is regulated by interactions with specific binding proteins (IGFBPs). The objective of this paper is to review available data on modifications of the IGF-I system in menopausal women during HRT, with particular attention on the differential effects of progestins. METHOD: All available reports on the effects of different forms of HRT have been taken into account. RESULTS: Available data suggest that different kinds of HRT have different effect on the IGF-I system, depending on route of administration, oestrogen dose, basal IGF-I values and type of progestin. Oestrogen administration (oestrogen replacement therapy (ERT)) reduces circulating IGF-I mainly through a hepatocellular effect. The decrease is sharper when oral ERT is used (first pass hepatic effect) and in women with higher basal IGF-I levels. The progestins endowed with androgenic effects--the 19-nortestosterone derivatives and, to a lesser extent, medroxyprogesterone acetate (MPA)--tend to reverse the IGF-I decrease induced by oral oestrogens. In contrast, progestins devoid of androgen-like hepatocellular and metabolic actions (e.g. dydrogesterone) do not interfere with the IGF-I decrease induced by oral oestrogens. Data on the effect of ERT on IGFBP-3 level are not consistent. Oral ERT, via hepatocellular actions (amplified by the first pass hepatic effect) causes a two to three-fold increase in IGFBP-1 levels. Androgenic progestins oppose the IGFBP-1 increase induced by oral oestrogens. Data on the effect of ERT and different progestins on the level of free IGF-I are scant and inconsistent. CONCLUSION: Even if some aspects need clarification, available data demonstrate that different progestins have differential effects on the circulating IGF-I system.


Assuntos
Fator de Crescimento Insulin-Like I/metabolismo , Progestinas/farmacologia , Terapia de Reposição de Estrogênios , Estrogênios/metabolismo , Estrogênios/farmacologia , Feminino , Humanos , Pós-Menopausa , Progestinas/metabolismo
7.
Maturitas ; 45(4): 283-91, 2003 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-12927315

RESUMO

UNLABELLED: During the menopause, levels of SHBG, IGF-I and IGFBPs are significantly modified by the use of different HRT regimens. OBJECTIVE: The aim of this study is to evaluate the influence of three different HRT regimens on serum levels of SHBG, IGF-I, IGFBP-1 and IGFBP-3 in postmenopausal women. METHODS: 41 postmenopausal women requesting HRT were enrolled in the study. Subjects were divided in three groups according to the therapy assigned; Group A: estradiol 2 mg/day+cyproterone acetate 1 mg/day in a cyclic sequential regimen; Group B: estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen; Group C: estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen. Blood samples were drawn before the start of hormonal treatment and after 6 months of HRT. Levels of SHBG, IGF-I, IGFBP-1 and IGFBP-3 in the serum were measured by means of a specific immunoassay. RESULTS: In group A, a significant increase of SHBG, no change of IGFBPs and a significant decrease of IGF-I were observed; in group B and in group C, no significant variations for any of the parameters were recorded. CONCLUSIONS: The association of cyproterone acetate to oral estradiol determines a significant reduction of IGF-I levels and an increase of SHBG; nevertheless, it does not seem to influence the serum levels of the IGF-I binding proteins. The treatment with oral continuous combined estrogens plus androgenic progestins, at low doses, produces minor, not significant, changes in the circulating levels of IGF-I, SHBG and IGFBPs.


Assuntos
Proteínas Sanguíneas/efeitos dos fármacos , Terapia de Reposição de Estrogênios , Noretindrona/análogos & derivados , Adulto , Ciproterona/administração & dosagem , Esquema de Medicação , Estradiol/administração & dosagem , Feminino , Humanos , Proteína 1 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue , Proteína 1 de Ligação a Fator de Crescimento Semelhante à Insulina/efeitos dos fármacos , Proteína 2 de Ligação a Fator de Crescimento Semelhante à Insulina/sangue , Proteína 2 de Ligação a Fator de Crescimento Semelhante à Insulina/efeitos dos fármacos , Fator de Crescimento Insulin-Like I/efeitos dos fármacos , Pessoa de Meia-Idade , Noretindrona/administração & dosagem , Acetato de Noretindrona , Pós-Menopausa , Globulina de Ligação a Hormônio Sexual/efeitos dos fármacos
8.
Clin Breast Cancer ; 12(3): 175-82, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22607767

RESUMO

UNLABELLED: This is a randomized controlled trial to test the effect of different doses of metformin in patients with breast cancer and without diabetes, with the aim of modifying the hormonal and metabolic parameters linked to breast cancer prognosis. Analysis of the results suggest that the dose of 1500 mg/d of metformin causes a significant reduction of insulin and testosterone serum levels. BACKGROUND: Serum levels of insulin and testosterone may affect both breast cancer (BC) incidence and prognosis. Metformin reduces hyperglycemia and insulin levels in patients with diabetes. In women without diabetes and with polycystic ovary syndrome, metformin lowers both insulin and testosterone levels. Patients with diabetes who are treated with metformin showed a lower risk of cancer; a protective effect of metformin also was observed for BC. Recently, studies on metformin use for prevention or treatment of BC have been proposed in patients who are not diabetic. The aim of the present study was to test the effect of different doses of metformin on serum levels of insulin and testosterone in those postmenopausal patients with breast cancer and without diabetes who have basal testosterone levels ≥0.28 ng/mL (median value). PATIENTS AND METHODS: A total of 125 eligible women were initially invited to take metformin 500 mg/d for 3 months. The 108 women who completed the first 3 months were invited to continue the study with metformin 1000 mg/d (500 mg twice a day [b.i.d.]) for 1 month. The women were then randomized into 2 groups, and, for the subsequent 5 months, 1 group increased the dose by taking metformin 1500 mg/d (500 mg 3 times a day [t.i.d.]), and the other group continued with metformin 1000 mg /d (500 [b.i.d.]). RESULTS: A total of 96 women completed the study: 43 women received 1500 mg/d, and 53 women received 1000 mg/d. The women who took 1500 mg/d showed a significant reduction of insulin level, HOMA-IR index (homeostasis model assessment-insulin resistance index), testosterone level, and free androgen index compared with women treated with 1000 mg/d. After treatment with 1500 mg/d, the insulin level decreased by 25% and the testosterone level decreased by 23%. CONCLUSION: Both these changes might have a prognostic importance.


Assuntos
Neoplasias da Mama/sangue , Carcinoma/sangue , Insulina/sangue , Metformina/farmacologia , Testosterona/sangue , Adulto , Idoso , Algoritmos , Neoplasias da Mama/tratamento farmacológico , Carcinoma/tratamento farmacológico , Diabetes Mellitus/sangue , Relação Dose-Resposta a Droga , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/farmacologia , Resistência à Insulina/fisiologia , Metformina/administração & dosagem , Pessoa de Meia-Idade
10.
Maturitas ; 62(4): 338-42, 2009 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-19118958

RESUMO

OBJECTIVE: Progestogens, particularly synthetic progestins, are widely used to contrast the clinical consequences of the relative hyperestrogenism that characterizes the years preceding the menopause. As a large body of data on postmenopausal hormone therapy (HT) demonstrates that the addition of synthetic progestins to estrogen increases the breast cancer risk compared to estrogen alone, it is important to evaluate if the use of progestogens in premenopausal years is associated with the risk of breast cancer. METHODS: Main literature data on the association with breast cancer risk of progestogens, either used alone in premenopausal years or added to estrogen in postmenopausal HT, were reviewed. RESULTS: Available data suggest that long-term current use of progestogens in premenopausal women after the age of 40 years can increase the risk of breast cancer. Consistently with the data on postmenopausal HT, the risk increase is higher for lobular cancer than for ductal cancer. CONCLUSIONS: The most important and widely accepted indications to the use of progestogens in the years preceding the menopause are anovulatory menstrual disorders, for which a limited period of treatment is generally sufficient. Awaiting for further data, when using progestogens for longer periods to treat other problems (endometriosis, cyclical mastalgia, etc.), the possibility of increased breast cancer risk and clinical benefits have to be weighed. Anyway, as micronized progesterone and dydrogesterone, at least when they were used in postmenopausal HT, seem to have, according to a large observational study, a safer risk profile on the breast, the preferential use of these preparations could be suggested.


Assuntos
Neoplasias da Mama/induzido quimicamente , Pré-Menopausa/efeitos dos fármacos , Progestinas/efeitos adversos , Adulto , Carcinoma Ductal de Mama/induzido quimicamente , Carcinoma Lobular/induzido quimicamente , Feminino , Terapia de Reposição Hormonal/efeitos adversos , Humanos , Progestinas/administração & dosagem , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA